Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a clinical study evaluating the efficacy and safety of rivaroxaban for stroke prevention in patients with atrial fibrillation (originally described in Japanese).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Collaborator: Janssen R&D, L.L.C.
• Treatments: Rivaroxaban; Warfarin

Criteria

Inclusion Criteria:

• 20 years or older

• Japanese male or female

• Non- valvular atrial fibrillation documented by ECG

• Patients with a risk of stroke and non-CNS systemic embolism

Exclusion Criteria:

• Significant mitral stenosis

• Patients in whom anticoagulants are contraindicated